Suppr超能文献

艰难梭菌感染:一种难治疾病的管理策略

Clostridium difficile infection: management strategies for a difficult disease.

作者信息

Khanna Sahil, Pardi Darrell S

机构信息

Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

出版信息

Therap Adv Gastroenterol. 2014 Mar;7(2):72-86. doi: 10.1177/1756283X13508519.

Abstract

Clostridium difficile was first described as a cause of diarrhea in 1978 and in the last three decades has reached an epidemic state with increasing incidence and severity in both healthcare and community settings. There also has been a rise in severe outcomes from C. difficile infection (CDI). There have been tremendous advancements in the field of CDI with the identification of newer risk factors, recognition of CDI in populations previously thought not at risk and development of better diagnostic modalities. Several treatment options are available for CDI apart from metronidazole and vancomycin, and include new drugs such as fidaxomicin and other options such as fecal microbiota transplantation. This review discusses the epidemiology, risk factors and outcomes from CDI, and focuses primarily on existing and evolving treatment modalities.

摘要

艰难梭菌于1978年首次被描述为腹泻的病因,在过去三十年中已呈流行状态,在医疗保健机构和社区环境中的发病率和严重程度均不断增加。艰难梭菌感染(CDI)导致的严重后果也有所增加。随着新的危险因素被识别、先前认为无风险人群中CDI得到认识以及更好的诊断方法的开发,CDI领域取得了巨大进展。除甲硝唑和万古霉素外,CDI还有几种治疗选择,包括新型药物如非达霉素以及其他选择如粪便微生物群移植。本综述讨论了CDI的流行病学、危险因素和后果,并主要关注现有的和不断发展的治疗方式。

相似文献

1
Clostridium difficile infection: management strategies for a difficult disease.
Therap Adv Gastroenterol. 2014 Mar;7(2):72-86. doi: 10.1177/1756283X13508519.
2
Clostridium difficile infection: Updates in management.
Indian J Gastroenterol. 2017 Jan;36(1):3-10. doi: 10.1007/s12664-016-0719-z. Epub 2016 Dec 20.
3
Clostridium difficile infection in older adults: a review and update on its management.
Am J Geriatr Pharmacother. 2012 Feb;10(1):14-24. doi: 10.1016/j.amjopharm.2011.12.004. Epub 2012 Jan 20.
4
Best strategies in recurrent or persistent Clostridium difficile infection.
Surg Infect (Larchmt). 2011 Jun;12(3):235-9. doi: 10.1089/sur.2010.080. Epub 2011 Jul 18.
5
Diagnosis and management of Clostridium difficile infection.
Clin Gastroenterol Hepatol. 2013 Oct;11(10):1216-23; quiz e73. doi: 10.1016/j.cgh.2013.03.016. Epub 2013 Mar 28.
6
Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options.
Drugs Aging. 2015 Aug;32(8):639-47. doi: 10.1007/s40266-015-0289-2.
7
Emerging therapies for Clostridium difficile infection - focus on fidaxomicin.
Infect Drug Resist. 2013 Jun 28;6:41-53. doi: 10.2147/IDR.S24434. Print 2013.
8
Clinical review of Clostridium difficile infection: an update on treatment and prevention.
Expert Opin Pharmacother. 2018 Nov;19(16):1759-1769. doi: 10.1080/14656566.2018.1524872. Epub 2018 Sep 25.
9
Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis.
Clin Infect Dis. 2014 Jun;58(11):1507-14. doi: 10.1093/cid/ciu128. Epub 2014 Mar 31.
10
Diagnosis and treatment of Clostridium difficile in adults: a systematic review.
JAMA. 2015 Jan 27;313(4):398-408. doi: 10.1001/jama.2014.17103.

引用本文的文献

2
Multi-Strain Probiotics: Synergy among Isolates Enhances Biological Activities.
Biology (Basel). 2021 Apr 13;10(4):322. doi: 10.3390/biology10040322.
3
co-infection with Enterohemorrhagic (EHEC)-a potentially fatal combination.
IDCases. 2020 May 8;21:e00797. doi: 10.1016/j.idcr.2020.e00797. eCollection 2020.
4
Real-world Experience of Bezlotoxumab for Prevention of Infection: A Retrospective Multicenter Cohort Study.
Open Forum Infect Dis. 2020 Mar 19;7(4):ofaa097. doi: 10.1093/ofid/ofaa097. eCollection 2020 Apr.
5
Cytoskeletal Tropomyosin as a Biomarker in Infection.
J Clin Med Res. 2019 Feb;11(2):98-105. doi: 10.14740/jocmr3696. Epub 2019 Jan 5.
6
Experience and Outcomes at a Specialized Clinical Practice.
Mayo Clin Proc Innov Qual Outcomes. 2017 May 19;1(1):49-56. doi: 10.1016/j.mayocpiqo.2017.05.002. eCollection 2017 Jul.
7
8
Routine Treatment-Resistant Infection during Recovery from Myxedema.
Case Rep Gastroenterol. 2017 Nov 29;11(3):748-754. doi: 10.1159/000484661. eCollection 2017 Sep-Dec.

本文引用的文献

2
Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011.
JAMA Intern Med. 2013 Jul 22;173(14):1359-67. doi: 10.1001/jamainternmed.2013.7056.
3
Is fidaxomicin worth the cost? An economic analysis.
Clin Infect Dis. 2013 Aug;57(4):555-61. doi: 10.1093/cid/cit346. Epub 2013 May 23.
4
Clinical factors associated with development of severe-complicated Clostridium difficile infection.
Clin Gastroenterol Hepatol. 2013 Nov;11(11):1466-71. doi: 10.1016/j.cgh.2013.04.050. Epub 2013 May 20.
5
An overview of fecal microbiota transplantation: techniques, indications, and outcomes.
Gastrointest Endosc. 2013 Aug;78(2):240-9. doi: 10.1016/j.gie.2013.03.1329. Epub 2013 May 2.
8
Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection.
Clin Infect Dis. 2013 Jun;56(12):1713-21. doi: 10.1093/cid/cit147. Epub 2013 Mar 13.
9
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.
Am J Gastroenterol. 2013 Apr;108(4):478-98; quiz 499. doi: 10.1038/ajg.2013.4. Epub 2013 Feb 26.
10
The epidemiology of Clostridium difficile infection in children: a population-based study.
Clin Infect Dis. 2013 May;56(10):1401-6. doi: 10.1093/cid/cit075. Epub 2013 Feb 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验